Most provokingly, pre-treatment with a cell permeable form of 2-hydroxyglutarate, product of the neomorphic IDH1 variant and usually considered an oncometabolite, sensitized AML cell lines with wild-type IDH1 to atRA induced differentiation [13]. Here, IDH1 is linked to acute myeloid leukemia.